// App-Quantinova.ai

: Cognitive Processing Speed Predicts Disease Progression in Secondary Progressive Multiple Sclerosis Post Hoc Analysis from the EXPAND Study

Researchers

Presenter

  • Iris-Katharina Penner

Principal Investigators

  • Gavin Giovannoni

  • Tanuja Chitnis

  • Patrick Vermersch

  • Sophie Arnould

  • Jeff Maca

  • Virginia DeLasHeras

  • Goeril Karlsson

  • Daniela Piani-Meier

  • Ludwig Kappos

  • Ralph H.B. Benedict

Medical Centers

  • Medical Faculty, Department of Neurology, Heinrich Heine University, Germany

  • COGITO Center for Applied Neurocognition and Neuropsychological Research, Düsseldorf, Germany

  • Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK

  • Department of Medicine, Brigham and Women's Hospital, Boston, MA

  • University Lille, INSERM U, CHU Lille, FHU Precise, Lille, France

  • Novartis AG, Basel, Switzerland

  • *(equal contribution) Neurologic Clinic and Policlinic, Department of Head, Spine and Neuromedicine, University Hospital of Basel, Basel, Switzerland

  • Research Center for Clinical Neuroimmunology and Neuroscience Basel (RCNB), Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland

  • *(equal contribution) Department of Neurology, University at Buffalo, Buffalo, NY, USA

Locations

  • Germany

  • United Kingdom

  • United States

  • France

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Dermatology

  • Genetic Disorder

Disease

  • Multiple Sclerosis

  • Ectodermal dysplasia-syndactyly syndrome

Biomarkers

  • N/A

Drug/Treatment

  • Siponimod

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved